CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

Clinical trial NCT02794961 · UNKNOWN

Trial details

NCT number: NCT02794961
Sponsor: Kai Lin Xu; Jun Nian Zheng
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Recurrent or Refractory B Cell Malignancy

Start date: 2016-06-01
Primary completion: 2018-06-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.